We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Crown

News List

Crown Bioscience Acquires OcellO contractpharma
May 08, 2021
Crown Bioscience, a JSR Life Sciences company and leader in preclinical services that help biopharmaceutical companies accelerate new drug development programs, has acquired OcellO B.V., a privately owned contract research organization located in the ...
Pfizer gets full US FDA nod for LORBRENA as first-line treatment for ALK-Positive metastatic NSCLC expresspharma
March 04, 2021
Approval is based on CROWN trial, which showed a 72 per cent reduction in risk of progression or death for treatment with LORBRENA vs. XALKORI.
LORBRENA significantly improves progression-free survival in first-line ALK-positive lung cancer pharmaceutical-business-review
August 11, 2020
Pfizer announced that the Phase 3 CROWN study of LORBRENA (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) met its primary endpoint by demonstrating significantly ...